All treatments were able to down-regulate the expression of TNF-α and IL-6, up-regulate the expression of TGF-β, rapidly improve hyperalgesia, grip strength, motor coordination, and nerve conduction velocity in rats with streptozotocin (STZ)-induced neuropathy, and improve neuropathy caused by T1D [143]. This evidence concerns the gene TGFB1 and neuropathy.